Ascendis Pharma A/S (BVMF:A1SN34)
77.44
+1.39 (1.83%)
At close: May 11, 2026
Ascendis Pharma Employees
Ascendis Pharma had 1,189 employees as of December 31, 2025. The number of employees increased by 172 or 16.91% compared to the previous year.
Employees
1,189
Change (1Y)
172
Growth (1Y)
16.91%
Revenue / Employee
4.38M BRL
Profits / Employee
2.51M BRL
Market Cap
68.68B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,189 | 172 | 16.91% |
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Jan 1, 2023 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Raia Drogasil | 75,190 |
| Fleury | 29,000 |
| Empreendimentos Pague Menos | 28,207 |
| Diagnósticos da América | 26,255 |
| Dimed S.A. Distribuidora de Medicamentos | 11,282 |
| Hypera | 10,564 |
| Blau Farmacêutica | 1,900 |
| Ouro Fino Saúde Animal Participações | 1,086 |
Ascendis Pharma News
- 1 day ago - Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 - GlobeNewsWire
- 4 weeks ago - Ascendis Pharma Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - Ascendis Pharma Earnings release: Q1 2026 - Filings
- 4 weeks ago - Ascendis Pharma Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 4 weeks ago - New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years - GlobeNewsWire
- 5 weeks ago - Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 - GlobeNewsWire
- 7 weeks ago - Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 - GlobeNewsWire
- 7 weeks ago - Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq - GlobeNewsWire